| 1 |
Aron JL, Akbari O. Regulatory T cells and type 2 innate lymphoid cell-dependent asthma[J]. Allergy, 2017, 72(8): 1148-1155.
|
| 2 |
Ferreira DS, Carvalho-Pinto RM, Gregório MG, et al. Airway pathology in severe asthma is related to airflow obstruction but not symptom control[J]. Allergy, 2018, 73(3): 635-643.
|
| 3 |
Mitchell PD, El-Gammal AI, O′Byrne PM. Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma[J]. Clin Pharmacol Ther, 2016, 99(1): 38-48.
|
| 4 |
Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy[J]. J Allergy Clin Immunol, 2017, 140(1): 162-169.e2.
|
| 5 |
Vennera MDC, Sabadell C, Picado C, et al. Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma.[J] .Thorax, 2018, 73(8): 782-784.
|
| 6 |
Li J, Kang J, Wang C, et al. Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: A randomized phase Ⅲ study[J]．Allergy Asthma Immunol Res, 2016, 8(4): 319-328.
|
| 7 |
Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab[J] . J Allergy Clin Immunol, 2014, 134(3): 560-567.e4.
|
| 8 |
Foster PS, Hogan SP, Ramsay AJ, et al. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model[J]. J Exp Med, 1996, 183(1): 195-201.
|
| 9 |
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma[J]. N Engl J Med, 2014, 371(13): 1189-1197.
|
| 10 |
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma.[J]. N Engl J Med, 2014, 371(13): 1198-1207.
|
| 11 |
Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials[J]. Lancet Respir Med, 2015, 3(4): 355-366.
|
| 12 |
Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: A randomized phase 3 study[J]. Chest, 2016, 150(4): 789-798.
|
| 13 |
Corren J, Weinstein S, Janka L, et al. Phase 3 Study of Reslizumab in patients with poorly controlled asthma: Effects across a broad range of eosinophil counts[J]. Chest, 2016, 150(4): 799-810.
|
| 14 |
Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted Iintravenous Reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous Mepolizumab[J]. Am J Respir Crit Care Med, 2018, 197(1): 38-46.
|
| 15 |
Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of Benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.[J]. Lancet, 2016, 388(10056): 2115-2127.
|
| 16 |
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial[J]．Lancet, 2016, 388(10056): 2128-2141.
|
| 17 |
Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-sparing effect of Benralizumab in severe asthma[J]. N Engl J Med, 2017, 376(25): 2448-2458.
|
| 18 |
Fahy JV. Type 2 inflammation in asthma-present in most, absent in many[J]. Nat Rev Immunol, 2015, 15(1): 57-65.
|
| 19 |
Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies[J]. Thorax, 2015, 70(8): 748-756.
|
| 20 |
Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of Lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials[J]. Lancet Respir Med, 2016, 4(10): 781-796.
|
| 21 |
Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of Tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Respir Med, 2015, 3(9): 692-701.
|
| 22 |
Chung KF. Tralokinumab unsuccessful for management of severe, uncontrolled asthma.[J]. Lancet Respir Med, 2018, 6(7): 480-481.
|
| 23 |
Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases.[J]. Expert Rev Clin Immunol, 2017, 13(5): 425-437.
|
| 24 |
Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma[J]. N Engl J Med, 2018, 378(26): 2486-2496.
|
| 25 |
Zayed Y, Kheiri B, Banifadel M, et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials[J]. J Asthma, 2018: 1-10.
|
| 26 |
Vazquez-Tello A, Halwani R, Hamid Q, et al. Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells[J]. J Clin Immunol, 2013, 33(2): 466-478.
|
| 27 |
Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn′s disease[J]. Am J Gastroenterol, 2016, 111(11): 1599-1607.
|
| 28 |
Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma[J]. N Engl J Med, 2017, 377(10): 936-946.
|
| 29 |
Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial[J]. Lancet Respir Med, 2016, 4(9): 699-707.
|
| 30 |
White C, Wright A, Brightling C. Fevipiprant in the treatment of asthma[J]. Expert Opin Investig Drugs, 2018, 27(2): 199-207.
|